Company profile

Inhatarget Therapeutics

Privately held: no public share price (Private ULB spin-off funded via Series A rounds plus Walloon Region grants. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.crunchbase.com/organization/inhatarget-therapeutics]) · Belgium

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
CIS-DPI
Phase 2
DNA (guanine N7 position)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.